Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / IRIX - Iridex's Cyclo G6 platform for treating glaucoma gets regulatory clearance in China

IRIX - Iridex's Cyclo G6 platform for treating glaucoma gets regulatory clearance in China

IRIDEX Corporation
Iridex (NASDAQ:IRIX) on Tuesday said it had got Chinese regulatory clearance to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases. IRIX and its distribution distribution partners Topcon and Clinico will launch the Cyclo G6 system and related probes in China beginning in Q3 2022. IRIX's Cyclo G6 platform treats glaucoma, one of the leading causes of blindness, through a micro-laser pulse instead of through incisions. IRIX stock +1.1% to $2.75 in morning trading.

For further details see:

Iridex's Cyclo G6 platform for treating glaucoma gets regulatory clearance in China
Stock Information
Company Name: IRIDEX Corporation
Stock Symbol: IRIX
Market: NASDAQ
Website: iridex.com
Menu
IRIX IRIX Quote IRIX Short IRIX News IRIX Articles IRIX Message Board
Get IRIX Alerts

News, Short Squeeze, Breakout and More Instantly...